Mar 15, 2022 / 05:30PM GMT
Luke England Sergott - Barclays Bank PLC, Research Division - Research Analyst
Good afternoon, everybody. I'm Luke Sergott. I cover life sciences tools and diagnostics at Barclays. It's my pleasure to have Prahlad Singh from PerkinElmer. And with that, if you want to make a couple of comments, and then we can just dig into some questions, if you'd like.
Prahlad R. Singh - PerkinElmer, Inc. - CEO, President & Director
Sure, Luke. Thank you. It's great to see everyone. It's good to meet in person. I think sort of to kick it off, Luke, maybe just talk about the company a little bit.
As you see the process of transformation that we have gone through over the past 5 years, we feel really good about where we are, obviously, covered over the last 24 months has been a major driver and a major factor in the company, but it has also given us the opportunity to continue to transform our portfolio. And where we stand today, 80% of PerkinElmer is in Life Sciences and Diagnostics.
And 3/4 of our revenue comes from consumables, reagents, assays, software
PerkinElmer Inc at Barclays Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot